ir.revivapharma.com Open in urlscan Pro
2a02:26f0:6c00::210:ba89  Public Scan

Form analysis
1 forms found in the DOM

GET /

<form class="views-exposed-form" data-drupal-selector="views-exposed-form-widget-sec-filings-table" action="/" method="get" id="views-exposed-form-widget-sec-filings-table" accept-charset="UTF-8">
  <div class="form--inline clearfix">
    <div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper" id="edit-actions"><input data-drupal-selector="edit-reset" type="submit" id="edit-reset" name="op" value="Reset"
        class="button js-form-submit form-submit visually-hidden">
    </div>
  </div>
</form>

Text Content

Skip to main navigation


   INVESTOR RELATIONS

 * Overview
 * News & Events
   Press Releases Events Presentations Publications
 * Financial Info
   SEC Filings Annual Reports Quarterly Results
 * Stock
   Stock Quote & Chart Historic Price Lookup
 * Governance
   Documents & Charters Leadership Board of Directors Advisors Committee
   Composition
 * Shareholder Resources
   FAQs Email Alerts Contact IR RSS Feeds




INVESTOR RELATIONS

CORPORATE PROFILE

Reviva Pharmaceuticals Holdings, Inc., (“Reviva”) headquartered in Cupertino,
California, is a clinical-stage biopharmaceutical company that discovers,
develops and seeks to commercialize next-generation therapeutics for diseases
representing significant unmet medical needs and burden to society, patients,
and their families. Reviva’s current pipeline focuses on the central nervous
system, respiratory, and metabolic diseases. Reviva is using chemical genomics
driven technology platform and proprietary chemistry to develop new medicines.
Reviva’s pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and
RP1208. Both are new chemical entities discovered in-house. Reviva has been
granted composition of matter patents for both RP5063 and R1208 in the United
States (U.S.), Europe, and several other countries.

Reviva’s lead drug candidate, RP5063, is ready for continued clinical
development for multiple neuropsychiatric indications. These include
schizophrenia, bipolar disorder (BD), major depressive disorder (MDD),
behavioral and psychotic symptoms, dementia or Alzheimer’s disease (BPSD),
Parkinson’s disease psychosis (PDP), and attention deficit hyperactivity
disorder (ADHD). Furthermore, RP5063 is also ready for clinical development for
two respiratory indications — pulmonary arterial hypertension (PAH) and
idiopathic pulmonary fibrosis (IPF). The U.S. Food and Drug Administration (FDA)
has granted Orphan Drug designation to RP5063 for the treatment of PAH in
November 2016 and IPF in April 2018.

 


VIEW ALL ABOUT

 * Learn More

NASDAQ CM: RVPH
$2.30 -0.0124 (-0.54%)

Data Provided by Refinitiv. Minimum 15 minutes delayed.


NEWS RELEASES

Sep 26, 2022
Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor
Conference
Sep 07, 2022
Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global
Investment Conference
Sep 06, 2022
Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct
Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq
Rules




VIEW ALL NEWS

 * View All


EVENTS

Sep 28, 2022 at 9:00 AM EDT
Lytham Partners Fall 2022 Investor Conference (Virtual Conference)
Sep 12 - Sep 14, 2022
H.C. Wainwright 24th Annual Global Investment Conference
Jun 27, 2022 at 9:30 AM EDT
H.C. Wainwright 1st Annual Mental Health Conference




VIEW ALL EVENTS

 * View All


SEC FILINGS

Oct 06, 2022
S-1
Oct 03, 2022
4
Sep 19, 2022
D
Sep 12, 2022
4


VIEW ALL SEC

 * View All




SHAREHOLDER TOOLS

 * 
   Print Page
 * 
   Email Alerts
 * 
   RSS
 * 
   FAQs

 * © Reviva Pharmaceuticals © 2022. All Rights Reserved.